MX2023001775A - El uso de microbios variovorax como un tratamiento alternativo para la coccidiosis. - Google Patents
El uso de microbios variovorax como un tratamiento alternativo para la coccidiosis.Info
- Publication number
- MX2023001775A MX2023001775A MX2023001775A MX2023001775A MX2023001775A MX 2023001775 A MX2023001775 A MX 2023001775A MX 2023001775 A MX2023001775 A MX 2023001775A MX 2023001775 A MX2023001775 A MX 2023001775A MX 2023001775 A MX2023001775 A MX 2023001775A
- Authority
- MX
- Mexico
- Prior art keywords
- coccidiosis
- direct effect
- gut
- treatment
- animals
- Prior art date
Links
- 208000003495 Coccidiosis Diseases 0.000 title abstract 3
- 206010023076 Isosporiasis Diseases 0.000 title abstract 3
- 241001478283 Variovorax Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000009471 action Effects 0.000 abstract 2
- 230000007246 mechanism Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000223924 Eimeria Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000021017 Weight Gain Diseases 0.000 abstract 1
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000282 effect on parasite Effects 0.000 abstract 1
- 230000036541 health Effects 0.000 abstract 1
- 230000008088 immune pathway Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000037452 priming Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Birds (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Los compuestos capaces de modular selectivamente la vía de señalización de TLR proporcionan un método de tratamiento mejorado para una amplia variedad de enfermedades tanto en animales como en seres humanos. Los mecanismos de acción en el tratamiento y/o prevención de la coccidiosis y otras afecciones relacionadas con la inflamación intestinal son a través de un efecto directo sobre las vías inmunitarias innatas y adaptables. Los resultados posteriores son mejoras en los parámetros de rendimiento relacionados con la salud intestinal (incluyendo la alteración de los microbios intestinales, las tasas de conversión y las ganancias de peso corporal, entre otros). Cuando se administran a animales, los bioactivos del compuesto de la invención descrito mitigan los efectos de la coccidiosis a través de una respuesta inmune mejorada en lugar de un efecto directo sobre los parásitos, tales como el parásito Eimeria. Los mecanismos de acción del compuesto y método de la invención descritos son a través del cebado del sistema inmunitario en lugar de un efecto directo sobre los patógenos, por lo que no hay riesgo de que se desarrolle resistencia al tratamiento.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064706P | 2020-08-12 | 2020-08-12 | |
| PCT/US2021/045744 WO2022036096A1 (en) | 2020-08-12 | 2021-08-12 | The use of variovorax microbes as an alternative treatment for coccidiosis |
| US17/400,790 US20220048958A1 (en) | 2020-08-12 | 2021-08-12 | Use of variovorax microbes as an alternative treatment for coccidiosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001775A true MX2023001775A (es) | 2023-03-10 |
Family
ID=80223924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001775A MX2023001775A (es) | 2020-08-12 | 2021-08-12 | El uso de microbios variovorax como un tratamiento alternativo para la coccidiosis. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220048958A1 (es) |
| EP (1) | EP4178598A1 (es) |
| JP (1) | JP2023537960A (es) |
| CN (1) | CN116033923A (es) |
| AU (1) | AU2021326515A1 (es) |
| BR (1) | BR112023001738A2 (es) |
| CA (1) | CA3187128A1 (es) |
| MX (1) | MX2023001775A (es) |
| PE (1) | PE20230984A1 (es) |
| WO (1) | WO2022036096A1 (es) |
| ZA (1) | ZA202300973B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3177327A1 (en) * | 2020-05-14 | 2021-11-18 | Andrew A. Dahl | Use of tlr4 modulator in the treatment of coccidiosis |
| WO2023220272A1 (en) * | 2022-05-12 | 2023-11-16 | Can Technologies, Inc. | Compositions and methods for the treatment and prevention of clostridium associated disease |
| WO2023220275A1 (en) * | 2022-05-12 | 2023-11-16 | Can Technologies, Inc. | Compositions and methods for the treatment and prevention of coccidiosis infection |
| WO2023220281A1 (en) * | 2022-05-12 | 2023-11-16 | Can Technologies, Inc. | Compositions and methods for the treatment and prevention of coinfection with eimeria and clostridium |
| JP7479620B1 (ja) | 2023-09-19 | 2024-05-09 | 有限会社バイオメディカルリサーチグループ | リポ多糖、リポ多糖製造方法及びリポ多糖配合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001025254A2 (en) * | 1999-10-04 | 2001-04-12 | University Of Maryland Biotechnology Institute | Novel adjuvant comprising a lipopolysaccharide antagonist |
| FI112088B (fi) * | 2001-10-17 | 2003-10-31 | Clewer Ltd Oy | Eettereitä hajottavia bakteereita ja niiden käyttö |
| US20060257411A1 (en) * | 2005-05-06 | 2006-11-16 | Bruce Beutler | Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway |
| US8088396B2 (en) * | 2006-03-01 | 2012-01-03 | University Of Iowa Research Foundation | Isolated complexes of endotoxin and modified MD-2 |
| US8603518B2 (en) * | 2006-05-01 | 2013-12-10 | Universiteit Gent | Hydroxybutyrate and poly-hydroxybutyrate as components of animal feed or feed additives |
| BR112019015140A2 (pt) * | 2017-01-23 | 2020-04-14 | Univ Florida | indução de imunidade protetora contra antígenos |
| EP3876750A4 (en) * | 2018-11-08 | 2022-05-25 | DSM IP Assets B.V. | METHODS TO SUPPORT GASTROINTESTINAL HOMEOSTASIS |
-
2021
- 2021-08-12 AU AU2021326515A patent/AU2021326515A1/en active Pending
- 2021-08-12 BR BR112023001738A patent/BR112023001738A2/pt unknown
- 2021-08-12 CA CA3187128A patent/CA3187128A1/en active Pending
- 2021-08-12 JP JP2023509572A patent/JP2023537960A/ja active Pending
- 2021-08-12 PE PE2023000249A patent/PE20230984A1/es unknown
- 2021-08-12 WO PCT/US2021/045744 patent/WO2022036096A1/en unknown
- 2021-08-12 CN CN202180055783.1A patent/CN116033923A/zh active Pending
- 2021-08-12 MX MX2023001775A patent/MX2023001775A/es unknown
- 2021-08-12 EP EP21856718.8A patent/EP4178598A1/en active Pending
- 2021-08-12 US US17/400,790 patent/US20220048958A1/en active Pending
-
2023
- 2023-01-23 ZA ZA2023/00973A patent/ZA202300973B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3187128A1 (en) | 2022-02-17 |
| EP4178598A1 (en) | 2023-05-17 |
| ZA202300973B (en) | 2024-05-30 |
| PE20230984A1 (es) | 2023-06-21 |
| WO2022036096A1 (en) | 2022-02-17 |
| US20220048958A1 (en) | 2022-02-17 |
| CN116033923A (zh) | 2023-04-28 |
| BR112023001738A2 (pt) | 2023-03-07 |
| JP2023537960A (ja) | 2023-09-06 |
| AU2021326515A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202300973B (en) | The use of variovorax microbes as an alternative treatment for coccidiosis | |
| Dixit | Can moderate intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19? | |
| MX2018009764A (es) | Solucion de bloqueo de cateter y terapia de bloqueo de cateter. | |
| MX2018002507A (es) | Metodo para la inhibicion de la absorcion de lipidos y/o la promocion de excrecion de lipidos usando d-psicosa. | |
| Improta-Caria et al. | Physical exercise and immune system: perspectives on the COVID-19 pandemic | |
| Friel et al. | A nutritional supplement formula for influenza A (H5N1) infection in humans | |
| WO2016159582A3 (ko) | 형개 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스용 조성물 | |
| Hamedchaman et al. | Exercise during coronavirus pandemic: two sides of the same coinintensity-specific effect of physical training on innate and acquired immune system of human | |
| Chamorro-Viña et al. | Excessive exercise and immunity: the J-shaped curve | |
| WO2020055547A3 (en) | Methods and compositions for honey bee health | |
| Athanasiou et al. | How does the Immune response to exercise differ from the immune response to infection? how can this be applied while advising athletes regarding return to activity/competition | |
| Mishra et al. | Healthy life style practices to combat COVID-19 pandemic–A mini review | |
| Sutili et al. | Clove Oil, eugenol effective anesthetics for silver catfish, other Brazilian species | |
| JP5775096B2 (ja) | インフルエンザの治療剤または予防剤 | |
| Gupta et al. | Physical Activity, Yoga and Meditation in Improving Immunity and Fighting Against Viral Respiratory Infections-A Systematic Review.(An Aid to COVID-19 and such Pandemics) | |
| He et al. | Effectiveness of Xiang-Qi-Tang against avian pathogenic Escherichia coli | |
| WO2010140855A2 (ko) | 복분자 추출물을 포함하는 심장비대증의 치료, 예방 또는 완화용 약제학적 조성물 또는 기능성 식품조성물 | |
| Egbe-Nwiyi et al. | The therapeutic efficacy of artesunate and diminazene in the treatment of experimental Trypanosoma brucei brucei infection in rats | |
| Sule et al. | The protective nature of Acalypha wilkensiana muell arg. leaves on CCL4-induced hepatotoxicity in wistar rats. | |
| Intizor et al. | USE OF NATURAL RESOURCES IN COMBINATION WITH CHEMICAL TREATMENTS FOR INFLUENZA | |
| Zhang | How to Treat Cancer Properly: Opinion | |
| Caria et al. | Physical Exercise and Immune System: Perspectives on the COVID-19 pandemic | |
| Ciupa et al. | Zincum metallicum 5cH increases survival and improves clinical mice infected with Trypanosoma cruzi | |
| Iribhogbe et al. | Antioxidant based combination therapy in malaria: in vivo study in plasmodium berghei infected mice | |
| Traifalgar | Development of immunostimulant for mud crab, Scylla serrata |